Bayer Partners with Iambic Therapeutics to Advance Drug Discovery with AI

Smart Tech Bayer Partners with Iambic Therapeutics to Advance Drug Discovery with AI

2026-07-14 Source: Press release Bayer 2 min Reading Time

Related Vendor

Bayer has collaborated with Iambic Therapeutics to discover new medicines using Iambic’s AI-driven platform. With this move, Bayer aims to identify novel drug entry points and differentiated molecules to address otherwise hard-to-drug targets.

Bayer and Iambic Therapeutics recently announced a drug discovery collaboration. (Source: Bayer) — Bayer and Iambic Therapeutics recently announced a drug discovery collaboration.
(Source: Bayer)

Berlin/Germany – Bayer and Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, recently announced a drug discovery collaboration in which Bayer will discover new medicines using Iambic’s AI-driven platform. The collaboration is focused on small molecule discovery.

The collaboration will leverage Iambic’s AI-driven drug discovery platform, including its flagship AI technologies, Enchant & Neuralplexer, to identify novel drug entry points and differentiated molecules to address otherwise hard-to-drug targets that will enhance Bayer’s early portfolio.

“This collaboration exemplifies our shared ambition to harness AI as a strategic driver of innovation in drug discovery and our focus on building high-impact collaborations that translate cutting-edge technology into patient value,” said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer Pharmaceuticals. “By collaborating with Iambic, we bring together complementary capabilities to accelerate scientific insights and improve decision-making across the R&D value chain.”

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

Traditional drug discovery takes 10-15 years and costs around 2.6 billion dollars, yet more than 90 percent of candidates fail in clinical trials. By using AI-based molecular optimization, the collaboration aims to identify differentiated hit molecules, accelerate optimization timelines, and strengthen Bayer's pipeline ahead of the next decade.

“Iambic is proving that better technology leads to better medicines, both in our own hands and with visionary partners like Bayer,” said Tom Miller, PhD, Co-Founder and CEO, Iambic. “Through this collaboration, Bayer secures access to industry-leading technology, including Iambic’s frontier AI models Enchant and Neuralplexer, and together we expand the universe of potential life-saving medicines.”

Under terms of the agreement Iambic will receive an upfront payment as well as milestone and royalty payments.

(ID:50898427)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.